会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 13. 发明公开
    • 피롤로피리미디논 유도체와 이의 제조방법 및 이의 용도
    • 吡咯烷酮衍生物,其制备方法及其用途
    • KR1020030086911A
    • 2003-11-12
    • KR1020030027197
    • 2003-04-29
    • 에스케이케미칼주식회사주식회사 인투젠
    • 김대기이주영임광진최진영김재선류제호정재윤이준원김태곤서정우한혜영김택수정인호
    • C07D487/04
    • C07D487/04
    • PURPOSE: pyrrolopyrimidinone derivatives, a preparation process thereof and the use thereof are provided. The compounds have improved selective PDE V(cGMP specific PDE) inhibiting activity, so that they can be useful for treatment of diseases associated with PDE V. CONSTITUTION: Pyrrolopyrimidinone derivatives of the formula 1, pharmaceutically acceptable salts and solvates thereof are provided, wherein R1 is hydrogen, one or more fluoro optionally substituted C1-C3 alkyl; R2 is hydrogen, hydroxy, C1-C3 alkoxy, and one or more fluoro optionally substituted C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, or C2-C6 alkynyl; R4 is one or more fluoro optionally substituted C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or C3-C6 cycloalkyl; W is N or CH; n is an integer of 1 to 6; R5 is COR6, COOR6 or COCH(R7)NH2; R6 is phenyl or aromatic heterocycle optionally substituted by 1 to 4 substituents selected from halogen, C1-C4 alkyl, C1-C4 alkoxy, OH, NH2, NO2, CN, COOH, C1-C4 aminoalkyl, C1-C4 alkylamino, C1-C4 acyl, C1-C4 acylamino, C1-C4 alkylthio, C1-C4 perfluoroalkyl, C1-C4 perfluoroalkoxy and C1-C4 alkoxycarbonyl, C1-C16 alkyl, C2-C16 alkenyl or C2-C16 alkynyl optionally substituted by 1 to 4 substituents selected from one or more halogen, C1-C4 alkoxy, OH, NH2, NO2, CN, COOH, C1-C4 aminoalkyl, C1-C4 alkylamino, C1-C4 acyl, C1-C4 acylamino, C1-C4 alkylthio, C1-C4 perfluoroalkyl, C1-C4 perfluoroalkoxy, C1-C4 alkoxycarbonyl, phenyl and aromatic heterocycle; and R7 is natural amino acid residue.
    • 目的:提供吡咯并嘧啶酮衍生物及其制备方法及其用途。 所述化合物具有改善的选择性PDE V(cGMP特异性PDE)抑制活性,因此它们可用于治疗与PDE V相关的疾病。构成:提供式1的吡咯并嘧啶酮衍生物,其药学上可接受的盐和溶剂合物,其中R1 一个或多个氟任选取代的C 1 -C 3烷基; R 2是氢,羟基,C 1 -C 3烷氧基和一个或多个氟任选取代的C 1 -C 6烷基,C 3 -C 6环烷基,C 2 -C 6烯基或C 2 -C 6炔基; R4是一个或多个氟任选取代的C 1 -C 6烷基,C 2 -C 6烯基,C 2 -C 6炔基或C 3 -C 6环烷基; W是N或CH; n为1〜6的整数。 R5是COR6,COOR6或COCH(R7)NH2; R6是任选被1至4个选自卤素,C 1 -C 4烷基,C 1 -C 4烷氧基,OH,NH 2,NO 2,CN,COOH,C 1 -C 4氨基烷基,C 1 -C 4烷基氨基,C 1 -C 4的取代基取代的苯基或芳族杂环 酰基,C 1 -C 4酰氨基,C 1 -C 4烷硫基,C 1 -C 4全氟烷基,C 1 -C 4全氟烷氧基和C 1 -C 4烷氧基羰基,C 1 -C 16烷基,C 2 -C 16链烯基或任选被1至4个选自 一个或多个卤素,C 1 -C 4烷氧基,OH,NH 2,NO 2,CN,COOH,C 1 -C 4氨基烷基,C 1 -C 4烷基氨基,C 1 -C 4酰基,C 1 -C 4酰氨基,C 1 -C 4烷硫基,C 1 -C 4全氟烷基, C1-C4全氟烷氧基,C1-C4烷氧基羰基,苯基和芳族杂环; 而R7是天然氨基酸残基。
    • 16. 发明授权
    • 2-아미노-9-(3-히드록시메틸-4-알콕시카르보닐옥시부트-1-일)퓨린 및 이를 함유하는 약학조성물
    • 2-氨基-9-(3-羟基甲基-4-烷氧基羰基)-1-YL)嘌呤和含有其的药物组合物
    • KR100257663B1
    • 2000-08-01
    • KR1019980006924
    • 1998-03-03
    • 에스케이케미칼주식회사
    • 김대기이남규장기영임광진김영우조용백최원선정인호김택수김기협
    • C07D473/32
    • PURPOSE: Provided is 2-amino-9-(3-hydroxymethyl-4-alkoxycarbonyloxybut-1-yl)purine having good anti-viral effects even with a small amount. And a pharmaceutical composition including it is also provided. CONSTITUTION: 2-amino-9-(3-hydroxymethyl-4-alkoxycarbonyloxybut-1-yl)purine is manufactured by the next steps of: i) reacting a compound of the formula (2) with 1,1'-carbonyldiimidazole in the presence of tetrahydrofuran (THF) as solvent for 3-72 hours to manufacture a cyclic compound of the formula (3); ii) reacting the compound (3) in the presence of Pd/C as catalyst and THF as solvent at 10-50 deg.C for 1-24 hours under 15-60psi to obtain alcohol of the formula (4); iii) reacting the compound (4) with MeSO2Cl in the presence of CH2Cl2 as solvent and Et3N at -20-50deg.C for 1-24 hours to manufacture methylsulfonyl ester compound of the formula (5); iv) reacting the compound (5) with 2-amino-6-chloropurine in the presence of Cs2CO3 and DMF as solvent at 0-100deg.C for 1-72 hours to manufacture a compound of the formula (6); v) reacting the compound (6) in the presence of Et3N and CH3CN-DMF as solvent and Pd/C as catalyst at 10-50deg.C for 1-72 hours under 15-60psi to manufacture 6-deoxy compound of the formula (7); and vi) reacting the compound (7) in the presence of chloroform as solvent and silica gel for 1-72 hours.
    • 目的:提供即使少量具有良好抗病毒作用的2-氨基-9-(3-羟甲基-4-烷氧基羰基氧基丁-1-基)嘌呤。 还提供了包含它的药物组合物。 构成:通过下列步骤制备2-氨基-9-(3-羟基甲基-4-烷氧基羰基氧基丁-1-基)嘌呤:i)使式(2)化合物与1,1'-羰基二咪唑在 存在四氢呋喃(THF)作为溶剂3-72小时以制备式(3)的环状化合物; ii)使化合物(3)在Pd / C作为催化剂存在下,THF作为溶剂在10-50℃下反应1-25小时,得到式(4)的醇; iii)将化合物(4)与MeSO 2 Cl在CH 2 Cl 2作为溶剂和Et 3 N存在下在-20-50℃反应1-24小时以制备式(5)的甲磺酰酯化合物; iv)在0-100℃下,在Cs 2 CO 3和DMF作为溶剂存在下使化合物(5)与2-氨基-6-氯嘌呤反应1-72小时以制备式(6)化合物; v)使化合物(6)在Et 3 N和CH 3 CN-DMF作为溶剂和Pd / C作为催化剂的存在下在10〜50℃下在15-60psi下反应1-72小时,制备式(6)的6-脱氧化合物 7); 和vi)使化合物(7)在氯仿存在下作为溶剂和硅胶反应1-72小时。